Yes, disappointing to say the least. But let's be real here. They are significantly expanding their systemtic testing and their
base. Yet, even if revenues were better than previous quarter they would NEED, imperatively need to raise cash. Going forward it looks more probable with respect to buyout. Another secondary quite definitely or buyout at 3.50+ In any case this is not going UNDER, That thinking is total BS!